US Patent No: 6,218,506

Number of patents in Portfolio can not be more than 2000

Amyloid .beta. protein (globular assembly and uses thereof)

3 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid .beta. peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
NORTHWESTERN UNIVERSITYEVANSTON, IL810
THE UNIVERSITY OF SOUTHERN CALIFORNIALOS ANGELES, CA813

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barlow, Ann Evanston, IL 4 111
Chromy, Brett A Evanston, IL 15 194
Finch, Caleb E Altadena, CA 6 177
Klein, William L Lakewood, CA 33 396
Krafft, Grant A Glenview, IL 30 271
Lambert, Mary P Glenview, IL 27 260
Morgan, Todd Kaysville, UT 12 127
Rozovsky, Irina Pasadena, CA 4 111
Wals, Pat Los Angeles, CA 4 111

Cited Art Landscape

  • No Cited Art to Display

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
MERCK SHARP & DOHME CORP. (3)
7,731,962 Anti-ADDL monoclonal antibody and use thereof 0 2006
8,105,593 Anti-ADDL monoclonal antibody and use thereof 0 2010
8,420,093 Anti-ADDL monoclonal antibody and use thereof 0 2012
 
Other [Check patent profile for assignment information] (1)
8,859,628 Method for preventing, treating and diagnosing disorders of protein aggregation 0 2004
 
IMIPLEX LLC (1)
8,993,714 Streptavidin macromolecular adaptor and complexes thereof 0 2010
 
WYETH LLC (13)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 39 2001
7,582,733 Humanized antibodies that recognize beta amyloid peptide 18 2002
7,256,273 Humanized antibodies that recognize beta amyloid peptide 47 2003
7,179,892 Humanized antibodies that recognize beta amyloid peptide 58 2003
7,871,615 Humanized antibodies that recognize beta amyloid peptide 10 2004
8,916,165 Humanized Aβ antibodies for use in improving cognition 0 2005
7,625,560 Humanized antibodies that recognize beta amyloid peptide 18 2005
7,700,751 Humanized antibodies that recognize β-amyloid peptide 3 2007
8,613,920 Treatment of amyloidogenic diseases 0 2007
8,128,928 Humanized antibodies that recognize beta amyloid peptide 1 2007
8,003,097 Treatment of cerebral amyloid angiopathy 1 2008
8,784,810 Treatment of amyloidogenic diseases 0 2008
9,067,981 Hybrid amyloid-beta antibodies 0 2009
 
JANSSEN SCIENCES IRELAND UC (3)
6,913,745 Passive immunization of Alzheimer's disease 57 2000
9,051,363 Humanized antibodies that recognize beta amyloid peptide 0 2007
7,893,214 Humanized antibodies that recognize beta amyloid peptide 8 2007
 
BIOARCTIC NEUROSCIENCE AB (7)
8,106,164 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 6 2005
7,700,719 Arctic β amyloid protofibril 5 2007
8,025,878 Protofibril selective antibodies and the use thereof 4 2007
9,034,334 Protofibril selective antibodies and the use thereof 0 2011
8,409,575 Antibodies specific for amyloid beta protofibril 2 2011
8,404,459 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 1 2011
8,999,936 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 0 2013
 
CORNELL UNIVERSITY (1)
6,815,175 Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder 16 2002
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (11)
7,964,192 Prevention and treatment of amyloidgenic disease 4 1999
7,588,766 Treatment of amyloidogenic disease 10 2000
7,575,880 Method of screening an antibody for activity in clearing an amyloid deposit 10 2000
6,905,686 Active immunization for treatment of alzheimer's disease 48 2000
8,535,673 Prevention and treatment of amyloidogenic disease 0 2004
8,034,339 Prevention and treatment of amyloidogenic disease 3 2004
6,972,127 Prevention and treatment of amyloidogenic disease 53 2004
6,946,135 Prevention and treatment of amyloidogenic disease 39 2004
7,790,856 Humanized antibodies that recognize beta amyloid peptide 8 2006
8,642,044 Prevention and treatment of amyloidogenic disease 0 2007
8,034,348 Prevention and treatment of amyloidogenic disease 0 2007
 
ABBVIE DEUTSCHLAND GMBH & CO. KG (2)
7,902,328 Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof 10 2004
8,895,004 Method for the treatment of amyloidoses 0 2008
 
WASHINGTON UNIVERSITY (5)
7,771,722 Assay method for alzheimer's disease 3 2002
7,195,761 Humanized antibodies that sequester abeta peptide 48 2002
7,892,545 Humanized antibodies that sequester amyloid beta peptide 0 2008
8,444,977 Assay method for Alzheimer's disease 0 2010
8,591,894 Humanized antibodies that sequester amyloid beta peptide 0 2010
 
ACUMEN PHARMACEUTICALS, INC. (2)
9,006,283 Methods of modifying amyloid β oligomers using non-peptidic compounds 0 2007
8,962,677 Methods of restoring cognitive ability using non-peptidic compounds 0 2007
 
NORTHWESTERN UNIVERSITY (5)
7,811,563 Anti-addl antibodies and uses thereof 0 2005
7,780,963 Anti-ADDL antibodies and uses thereof 2 2005
8,128,930 Anti-ADDL antibodies and uses thereof 0 2010
8,889,138 Anti-ADDL antibodies and uses thereof 0 2010
8,383,113 Anti-ADDL antibodies and uses thereof 1 2012
 
ABBVIE INC. (7)
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
8,263,558 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins 0 2006
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
8,987,419 Amyloid-beta binding proteins 0 2011
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2011
9,062,101 Amyloid-beta binding proteins 0 2011
 
Eli Lilly and Company (1)
8,066,999 PEGylated Aβ fab 0 2008
 
AC IMMUNE SA (1)
7,772,375 Monoclonal antibodies that recognize epitopes of amyloid-beta 17 2006
 
KYOWA HAKKO KIRIN CO., LTD. (2)
8,333,967 Anti-Aβ oligomer humanized antibody 0 2010
8,303,954 Anti-Aβ oligomer humanized antibody 0 2010
 
APPLIED MOLECULAR EVOLUTION, INC. (3)
7,575,747 Aβ binding molecules 3 2004
8,105,597 Aβ binding molecules 0 2009
8,623,365 Aβ binding molecules 0 2011
 
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (1)
8,974,768 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates 0 2011
 
PLAXGEN, INC. (1)
8,932,558 Multi-subunit biological complexes for treatment of plaque-associated diseases 0 2008
 
GENENTECH, INC. (6)
7,892,544 Humanized anti-beta-amyloid antibody 12 2007
8,124,353 Methods of treating and monitoring disease with antibodies 3 2007
8,613,923 Monoclonal antibody 0 2008
8,048,420 Monoclonal antibody 3 2008
8,246,954 Methods of treating amyloidosis with humanized anti-beta-amyloid antibodies 2 2009
8,796,439 Nucleic acid molecules encoding a humanized antibody 0 2012
 
NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (1)
8,378,081 Antibodies that specifically bind to Aβ oligomers and uses thereof 3 2009
 
The University of Southern California (1)
7,638,283 Amyloid β protein (globular assembly and uses thereof) 3 2005
 
IMMUNAS PHARMA, INC. (2)
8,858,949 Antibodies that specifically bind to a beta oligomers and use thereof 0 2010
8,613,924 Antibodies that specifically bind to A beta oligomers and use thereof 0 2010
* Cited By Examiner